Omaha, Nebraska (PRWEB) March 24, 2009
Meningococcal disease (commonly referred to as meningitis or epidemic meningitis) is a serious, sometimes fatal bacterial infection that occurs worldwide. Since January 2009, local health officials in India have reported 230 deaths and 2,000 possible cases of meningitis in the northeastern states of Tripura, Meghalaya, and Mizoram. These states are in the part of India bordered by Bangladesh to the west and Myanmar (Burma) to the east. Authorities in India's northeastern Meghalaya region are trying to combat the outbreak of meningitis fever that has claimed around 132 lives and debilitated 900. After visiting the affected areas the team of experts said that most of the meningitis fever cases have been reported from slum areas where the people are forced to live in unhygienic conditions. Neena Dhaun reports.
JN-International Medical Corporation will shortly ship the 300,000 doses of the vaccine to affected areas in India. This first shipment will be followed by another 700,000 doses of Meningococcal meningitis vaccine to the region to stop the spread of the disease to other neighboring states including Bangladesh and Myanmar said Dr. Jeeri R. Reddy, the President and Scientific Director of the corporation.
JN International has stock piles of vaccine at its cold storage facilities in Burkina Faso in West Africa and in Singapore to help with the disease outbreaks in Africa and South Asia.
JN-International Medical Corporation:
JN-International Medical Corporation is a U.S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. An Inc 5000 corporation, making it the 95th ranking company in the United States and the 3rd biopharmaceutical global corporation, it produces Meningitis vaccine for which it holds the international intellectual property rights (IPR).
JN boasts a decade of achievements including prevention of mother-to-child transmission of HIV in South East Asia, development of inexpensive vaccine for Meningococcal meningitis serogroups A, C, Y&W-135 and lately the discovery of a new generation preventive and therapeutic vaccine for Stroke and neurological disorders. The R&D division of JN-International is currently researching and developing vaccines for the prevention and cure of Hepatitis C, Herpes, Tuberculosis and a preventive and therapeutic vaccine for major Neurological disorders. JN-International Medical Corporation (JNI), based in Omaha, Nebraska, USA has overseas business offices and clinical trial centers located in Abidjan, Ivory Coast in Africa and in Kuala Lumpur, Malaysia, with vaccine cold chain facilities in Burkina Faso and Singapore.
For more information:
Contact: Peter Grotzinger, director of public relations
JN-International Medical Corporation
# # #